**Table 4: Summary of treatment recommendations**

|  |  |  |
| --- | --- | --- |
| Disease manifestation | Treatment recommendation | Level of evidence |
| CONSENSUS |  |  |
| CNS disease* Microcephaly, CNS calcification, chorioretinitis
* White matter changes (or other abnormalities on MRI consistent with CMV disease) 1
 | Ganciclovir/valganciclovir Duration 6 months2 | Treatment:Quality A, Strength 1 (to treat)Duration:Quality B, Strength 2  |
| Other ‘severe’ disease (includes life threatening or severe single organ or multi-organ non-CNS disease) | Ganciclovir/valganciclovir Minimum of 6 weeks, up to 6 months2,3 | Treatment:Quality B, Strength 1Duration:Quality B, Strength 2 |
| ‘Mild’ disease – isolated or transient disease (e.g. jaundice, Petechiae, SGA in isolation)(max 2 abnormalities) | No treatment | Treatment:Quality C, Strength 2 (for no treatment) |
| No clinical or biochemical findings of disease (+/- detectable CMV viremia) | No treatment | Treatment:Quality D, Strength 1 (for no treatment) |
| MAJORITY OPINION – BUT NOT CONSENSUS |  |  |
| Isolated hearing deficit2,4 | Ganciclovir/valganciclovirDuration 6 months2 | Treatment:Quality C, Strength 1Duration:Quality C, Strength 2 |
| ‘Moderate’ disease (see text for definition)(e.g. multiple minor findings consistent with CMV disease)2 | Consider treatment following discussion with specialist Duration: Minimum of 6 weeks and up to 6 months2 | Treatment:Quality C, Strength 2Duration:Quality B, Strength 2 |

**Note: There is currently only evidence for starting treatment in the first month of life.**

**CNS: Central nervous system MRI: Magnetic Resonance Imaging**

1. In the case of isolated, non-specific, MRI findings that are not consistent with cCMV disease it was agreed that treatment is not necessarily indicated
2. Limited evidence without full consensus – see text for further description
3. It was suggested (without consensus) that treatment might continue in this group until the underlying clinical manifestation of disease (e.g. hepatitis) resolved since benefit of 6 months treatment is unclear.
4. No studies address this particular group although they were included in eligibility criteria for treatment in both published RCT’s of treatment.